African Journal of Cardiology and Cardiovascular Medicine
Editor-in-Chief: Dr. Mohd. Shahbaaz Khan | ISSN: 3136-9294 | Frequency: Biannual | Publication Format: Open Access | Language: English | Indexing/Listing :

Current Issue of African Journal of Cardiology and Cardiovascular Medicine

Volume 1, Issue 1, July 2025
Review Article

Efficacy and safety of PCSK9 inhibitors and inclisiran in achieving LDLcholesterol targets: A systematic review and meta-analysis

| Open Access

Erik A. Lindström1*

Afj.Card.Cardvm. 1(1) (2025) 38-46, DOI: https://doi.org/10.62587/AFJCCM.1.1.2025.38-46
Received: 15/01/2025|Accepted: 30/05/2025|Published: 25/07/2025

Abstract

Background: Low-Density Lipoprotein Cholesterol (LDL-C) is a principal causal driver of atherosclerotic cardiovascular disease, yet a substantial proportion of high-risk patients fail to reach guideline-recommended LDL-C targets on statin therapy alone. Proprotein convertase subtilisin-kexin type 9 (PCSK9) monoclonal antibodies and the small interfering RNA agent inclisiran offer complementary mechanisms of PCSK9 inhibition, and this systematic review and meta-analysis aimed to quantify their comparative efficacy in LDL-C lowering and target attainment together with their safety. Methods: PubMed, Scopus, Embase, and the Cochrane Central Register of Controlled Trials were searched to December 2025 for randomized controlled trials reporting placeboor control-corrected percentage LDL-C change with evolocumab, alirocumab, or inclisiran. Eight pivotal trials enrolling 53,719 participants were included. Random-effects models with the DerSimonian and Laird estimator generated pooled mean percentage reductions with 95% Confidence Intervals (CIs); prespecified subgroup analysis contrasted the two drug classes, and heterogeneity was assessed using the I-squared statistic. Results: The pooled placebo-corrected LDL-C reduction across all agents was 55.7% (95% CI 52.9 to 58.5). Reduction was greater with PCSK9 monoclonal antibodies (58.4%, 95% CI 55.9 to 61.0) than with inclisiran (50.6%, 95% CI 48.4 to 52.7), a difference of 7.9% points (p < 0.001). Heterogeneity was substantial overall and among monoclonal antibodies yet negligible within the inclisiran subgroup (I-squared 0.1%). LDL-C goal attainment was high with both classes, and adverse events were comparable to control apart from an excess of mild injection-site reactions. Conclusion: PCSK9 monoclonal antibodies and inclisiran both produced large, sustained LDL-C reductions and enabled the majority of high-risk patients to reach contemporary LDL-C targets, with a modestly greater effect for monoclonal antibodies and a favorable safety profile for both, supporting their role as effective options for patients not achieving targets on statin therapy.


Keywords: PCSK9 inhibitors, Inclisiran, LDL cholesterol, Goal attainment, Hypercholesterolemia, Meta-analysis

 Full text  Download  XML